Genistein Enhances the Efficacy of Cabazitaxel Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Cells

BACKGROUND: Cabazitaxel (Jevtana) has been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, most patients progress and become chemoresistant, which remains a major challenge in the management of advanced PCa. In this study, we investigated whether genis...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Prostate
Glavni autori: Zhang, Shumin, Wang, Yanru, Chen, Zhengjia, Kim, Sungjin, Iqbal, Shareen, Chi, Andrew, Ritenour, Chad, Wang, Yongqiang A., Kucuk, Omer, Wu, Daqing
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4499861/
https://ncbi.nlm.nih.gov/pubmed/23999913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22705
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items